COMMUNIQUÉS West-GlobeNewswire

VitalHub Reports Fourth Quarter 2025 Results
18/03/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 million Total Revenue up 52% YoY to $31.4 million Adjusted EBITDA⁽¹⁾ up 47% YoY to $7.4 million TORONTO, March 18, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental [...]
Ever Joint Claims Evaluated: What the Science Says About EverJoint Joint Support Ingredients
18/03/2026
A 2026 company-issued informational report outlining how Ever Joint positions its joint support formula, ingredient-level research context, oxidative stress claims, pricing structure, and what consumers should verify [...]
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03/2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine [...]
SnoreStop Throat Spray Claims Evaluated: Effective Anti-Snoring Oral Solution with Clinically Proven Ingredients
18/03/2026
A 2026 source-based informational overview of SnoreStop's doctor-developed oral spray formula as described in company materials, cited clinical study references, homeopathic ingredient research context, pricing [...]
Extendicare Announces Proposed Changes to Board of Directors
18/03/2026
MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair [...]
ADR Ratio Change
18/03/2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative [...]
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
18/03/2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth [...]
Big Ed's Meds Under Investigation: Safe FDA-Approved ED Medications for Men
18/03/2026
A company-informational report from Big Eds Meds LLC addressing common consumer search questions about the Big Ed's Meds telehealth platform, FDA-approved generic ED medication access, pricing, provider standards, and [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/03/2026
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
18/03/2026
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at [...]
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
18/03/2026
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 [...]
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
18/03/2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and [...]
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
18/03/2026
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/03/2026
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase [...]
Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
18/03/2026
DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]

Pages